about
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisImpact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyVoriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Achieving target voriconazole concentrations more accurately in children and adolescents.Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review.In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderSoftware for dosage individualization of voriconazole for immunocompromised patientsAntifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignanciesSteady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.Tissue penetration of antifungal agents.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Comparison of clinical pharmacology of voriconazole and posaconazole.Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Personalised dosing of medicines for children.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.Autoinduction of voriconazole metabolism in a child with invasive pulmonary aspergillosis.Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection.Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.Latest trends in fungal epidemiology inform treatment choices and stewardship initiatives.Population Pharmacokinetics of Voriconazole and CYP2C19 Polymorphisms for Optimizing Dosing Regimens in Renal Transplant Recipients.
P2860
Q28727508-CE0F651A-2802-46D5-A12C-DD2B1C88D360Q30491969-AA7653A2-D86C-47BE-BA2C-F5CA2D91AC3BQ33827819-C3DD4304-0C2D-4B2B-A172-E61CC2C8621FQ34138276-FE8679D2-AAD8-4AC0-9304-7C3B4B2C0AE5Q35607652-20204EC7-AF4C-47D9-98DF-A8466DEE0D01Q36172497-C744EE1D-BA04-4F49-8F55-58F266387628Q36273788-F1B6B099-2A57-48F1-8985-8B8A2C77F0E3Q36290764-5A2BC3F6-88DF-4F38-AEB1-2A4D85176FF8Q36757595-3F1D7F83-7279-45B2-8F2A-DA9CB32C399BQ36948094-14F51E11-72BD-486B-97CF-BED6C50905F0Q36969780-473C2E06-317C-4CB0-B1EE-592987191BD7Q36969849-C9B2FD11-D21D-49B6-9E7E-ECA745582645Q37544911-64ACB814-7F00-4120-BF05-E7EE9F2AC196Q37688257-A00D51A1-FCE0-4F62-8BE7-4C1BE4EB17E0Q37727651-3C30A2C7-0EC9-46C5-8FBF-708E14CB04CDQ38005226-8609B33C-F061-48E8-89B6-362075E9B3A2Q38193337-266F00AE-DA9B-4133-8508-B31240B6065CQ38362057-A67D61FA-5AAE-4C31-AA28-05CFCAA57F1EQ38738090-9FD51829-5275-40BE-831C-5D1FD6F5D127Q38749764-4B3BC4C2-4729-493D-B76E-5E31E4F0F9ACQ38775809-181845F1-43DD-442B-8201-0298ED9838F9Q38823930-27031FA9-538A-4D1B-A1AD-B3AB18EE78A2Q38931118-BB9FD75F-FD79-4DD8-9DDD-D4E30F378E9AQ39816665-9465DD20-6266-41D2-960F-03E601C74FABQ40637806-B248DEBF-44E7-4F5D-B74D-88ED1B0D183AQ41057395-5BF0A19B-54CC-4690-867E-F51E63562318Q43512563-71F71C14-9245-459F-81EC-937FFCF03A60Q47568169-F0F18963-42B3-48A2-95BA-90F61130F7E2Q48010621-A53C6D0F-8AA3-472B-92D6-2E70A6331DD1Q50028191-F4CE373C-63B7-449E-A0D3-32B4A7B1BA9AQ51110220-9C7F7DAD-68FC-4FFC-BBA4-43F916BB1E78Q51551309-62569B22-B433-4BC7-9871-5CBB01748492Q52614215-B24ADFD7-2A9F-4149-8F5E-D83E87A492AA
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Population pharmacokinetics of voriconazole in adults
@ast
Population pharmacokinetics of voriconazole in adults
@en
type
label
Population pharmacokinetics of voriconazole in adults
@ast
Population pharmacokinetics of voriconazole in adults
@en
prefLabel
Population pharmacokinetics of voriconazole in adults
@ast
Population pharmacokinetics of voriconazole in adults
@en
P2860
P356
P1476
Population pharmacokinetics of voriconazole in adults
@en
P2860
P304
P356
10.1128/AAC.00702-11
P407
P50
P577
2011-11-07T00:00:00Z